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Abstract Atopic dermatitis in humans and dogs is a chronic
relapsing allergic skin disease. Dogs show a spontaneous
disease similar to the human counterpart and represent a
model to improve our understanding of the immunological
mechanisms, the pathogenesis of the disease, and new therapy
development. The aim of the study was to determine the
frequency and phenotype of dendritic cells (DC) in the
epidermis and dermis of healthy, canine atopic dermatitis
lesional, and non-allergic inflammatory skin to further
validate the model and to obtain insights into the contribution
of DC to the pathogenesis of skin diseases in dogs. We first
characterized canine skin DC using flow-cytometric analysis
of isolated skin DC combined with an immunohistochemical
approach. A major population of canine skin dendritic cells
was identified as CD1c+CD11c+CD14−CD80+MHCII+-
MAC387− cells, with dermal DC but not Langerhans cells
expressing CD11b. In the epidermis of lesional canine atopic
dermatitis and non-allergic inflammatory skin, we found
significantly more dendritic cells compared with nonlesional
and control skin. Only in canine atopic dermatitis skin did
we find a subset of dendritic cells positive for IgE, in the
epidermis and the dermis. Under all inflammatory condi-
tions, dermal dendritic cells expressed more CD14 and
CD206. MAC387+ putative macrophages were absent in
healthy but present in inflamed skin, in particular during
non-allergic diseases. This study permits a phenotypic
identification and differentiation of canine skin dendritic
cells and has identified markers and changes in dendritic
cells and macrophage populations related to allergic and non-
allergic inflammatory conditions. Our data suggest the
participation of dendritic cells in the pathogenesis of canine
atopic dermatitis similar to human atopic dermatitis and
further validate the only non-murine spontaneous animal
model for this disease.
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Introduction
Atopic dermatitis (AD), also called atopic eczema, is a
chronic recurrent allergic skin disease with characteristic
clinical features that affects humans and domestic animals
[1]. The prevalence in children is between 15% and 30% of
which around 70% show spontaneous remission before
adolescence. Therefore, in adults, the prevalence is much
lower (2–10%), although atopic children often develop
asthma and allergic rhinitis, a disease connection called
“atopic March” [2]. Canine atopic dermatitis (cAD) affects
approximately 10–15% of the canine population [3, 4].
Spontaneous remission and the atopic March are very rare
in dogs [1].
In most cases, human AD (hAD) and cAD are associated
with allergen-specific IgE [4] and a dysfunction of the
epidermal barrier [1, 2]. The latter is considered a
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prerequisite for the penetration of high molecular-weight
allergens originating from pollens, house dust mite
products, microbes, and food [2]. Reduced expression of
epidermal filaggrin and increased TEWL, indicating
impaired epidermal barrier function, are also features of
cAD [5]. A genetic predisposition toward AD was shown
in dogs as well [6].
Dogs suffering from AD show very similar lesions in
type and distribution to hAD [1]. Increased staphyloccocal
colonization, recurrent bacterial, and yeast infections are
observed frequently and further contribute to pruritus, the
most common clinical sign of AD. Self-trauma can
aggravate secondary infections. The body parts typically
affected in dogs involve the feet and flexural areas of the
limbs, axillae, groin, pinnae, periocular, and perioral areas
[1, 2]. Like in man, there is no specific diagnostic test for
diagnosis of cAD. Diagnosis of cAD is based on clinical
criteria defined by Willemse [7], Prélaud [7, 8], and
recently Favrot [9] for dogs. In addition, relevant differen-
tial diagnoses such as scabies, flea-bite hypersensitivity,
food adverse reactions, and contact allergies should be
ruled out. For both humans and dogs, the histopathological
alterations of AD include a spongiotic dermatitis with a
mononuclear infiltrate, composed of T cells and dendritic
cells (DC) [1, 2]. The inflammatory reaction in hAD is
biphasic. The initial acute Th2 response dominated by IL-4,
IL-5, and IL-13 is 48 h after atopy patch test followed by a
chronic phase in which Th1 cells secreting IFN-γ, IL-12,
IL-5, and GM-CSF infiltrate the skin lesions [2]. In dogs,
only the initial Th2 response is typically found, and in
chronic lesions, the expressed cytokine pattern can be
variable [1].
DC represent a complex family of cells comprised of
multiple subsets with different origin, anatomical local-
ization, and function [10]. Besides their particular ability
to act as sentinels of the immune system by sensing
invading pathogens and taking up antigens and allergens,
they are most effective in antigen presentation and are able
to prime naive T cells [11], as well as regulating the
orientation of distinct T cell responses [10]. During the
pathogenesis of AD, it is considered that DC not only take
up the allergen but also stimulate key events promoting
the clinical manifestation [12]. Understanding these events
requires the consideration of DC heterogeneity in the skin. In
healthy skin, there are three cutaneous DC populations forming
a continuous network. These are the epidermal Langerhans
cells (LC) containing Birbeck granules (human LC are
characterized by CD1a+ CD11b−MHCII+, CD207+) [12], the
resident dermal DC in man composed of three major subsets a
CD1ahighCD4+CD14−CD16−CD206highCD207−CD209+, a
CD1lowCD4+CD14+CD16−CD206lowCD207−CD209+ popu-
lation [12], and plasmacytoid DC [13]. During inflammation,
there is an additional subset of dermal “inflammatory”
DC in the epidermis and dermis called inflammatory
epidermal DC (IDEC) based on their first description in
the epidermis. Their phenotype is CD1a+FcεRI+FcεRII+
IgE+CD206+CD11b+CD1b+MHCII+CD207−, and they
lack Birbeck granules [13]. Mouse models indicate that
these DC are of monocytic origin and may carry antigens
to the draining lymph nodes [11]. Monocytes may also
replenish LC under inflammatory conditions [14]. In hAD,
a significant infiltration of IDEC can be found [15]. All
epidermal and dermal DC populations in AD express
FcεRI, which is required to provoke eczematous skin
lesions [16, 17]. On ligation of FcεRI by IgE, LC produce
IL-16 and IL-13, which recruit monocytes, IDEC, and
CD4+ T cells to the skin. This in turn induces the
production of IgE [18] contributing to the Th2 response.
IDEC are considered responsible for the switch to the Th1
response in chronic hAD by producing IL-12 and IL-18
and releasing proinflammatory cytokines [2, 19]. In humans,
AD skin is practically devoid of pDC.
Due to the spontaneous occurrence and the similarities
between cAD with hAD, the dog is a good and unique
model to study disease pathogenesis and novel therapeutics
[1]. The disadvantage of mouse models are the artificial
induction required and the important differences in patho-
genesis as a consequence of this [4, 20]. Another interesting
aspect of the spontaneous cAD model is that dogs and
people live in the same physical environment, which is an
important factor in disease pathogenesis. The DC system of
the canine skin has not yet been characterized with
exception of one study on cAD describing an increase of
CD1+IgE+ cells in the epidermis and dermis [21].
Based on this, the aim of the present study was to
characterize the canine skin DC system in more detail in
healthy, atopic skin, and selected non-allergic inflammatory
skin disease in order to further develop the canine model,
and to demonstrate the involvement of DC in the
pathogenesis of cAD.
Materials and Methods
Animals
Control skin biopsies were taken from healthy laboratory
Beagles (which served as control dogs in toxicological
studies of Novartis Animal Health, Basel, Switzerland)
or from privately owned dogs euthanized for reasons not
related to this study. Skin biopsies from privately owned
dogs suffering of cAD or non-allergic inflammatory skin
diseases (NAI) were also obtained. All biopsies were
collected with the owner’s written consent. All proce-
dures were approved by the local animal welfare
authorities.
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Isolation and Analysis of Skin Dendritic Cells
Skin DCwere isolated as published previously [22]. Briefly, an
area of skin approximately 8×8 cm was clipped and collected
immediately after euthanasia, and kept on ice in RPMI 1640
(Invitrogen, Lubio Science, Luzern, Switzerland) supple-
mented with 2 mM L-glutamine (Sigma-Aldrich, Buchs,
Switzerland), 1% streptomycin and penicillin (Sigma), 10%
heat-inactivated FBS (Bioclot GmbH, Hollerbach, Germany),
and 1% fungizone (Sigma) up to 3 h until processing. The
skin was cleared of subcutaneous fat, cut into strips of 1–
2 mm, and incubated with 2.4 U/ml Dispase II (Roche
Diagnostics GmbH, Mannheim, Germany) at 37°C for
90 min. Epidermis and dermis were then separated with two
strong forceps and washed separately twice with PBS at 4°C.
To allow DC migration, the samples were incubated at 37°C
for 48 h in medium as described above. In addition, it was
supplemented with 1% Hepes (Invitrogen) and 40 ng/ml
human recombinant GM-CSF (kindly donated by Novartis
Pharma, Vienna, Austria) to enhance survival of DC.
Migrated cells were harvested by filtering the media through
a 70 μm Cell Strainer (BD Biosciences, San Jose, CA, USA)
to obtain a single cell suspension. Cells were counted and
double stained with a rat anti-canine MHC class II antibody
(Serotec, Oxford, UK) in combination with a panel of
different second monoclonal antibodies (mAb) against CD1c
(CA13.9H11), CD11b (CA163E10), CD11c (CAH.6A1),
CD45 (CA4.ID3), CD80 (CA24.5D4), and CD86
(CA24.5E4) (all kindly obtained from Dr. Peter Moore;
University of Davis, CA, USA); against IgE (D9) (kindly
donated by Dr. D. DeBoer; University of Wisconsin,
Madison, WS, USA); against CD4 (CA13.1E4), CD8 (CA9.
JD3), CD21 (CA2.1D6), and human CD40 (LOB7/6) (all
obtained from Serotec); against CD206 (3.29B1.10) (from
Beckman Coulter; Roissy, France); against CD14 (CAM36A)
(from VMRD; Pullman, WA, USA); and against MAC387
(from Dako; Baar, Switzerland). The mAb binding was
revealed using anti-mouse or anti-rat isotype specific
fluorescein isothiocyanate (FITC) or phycoerythrin con-
jugated goat F(ab’)2 Ig (Southern Biotech, Birmingham,
USA). Fluorescence intensities were quantified using a
LSRII or FACScan flow cytometer (BD Biosciences),
and data were processed using the FlowJo software (Tree
Star, Ashland, OR, USA).
Skin Biopsies
We collected lesional (groin area) and nonlesional (dorsal
flank) skin samples with 6-mm biopsy punches (Provet,
Lyssach, Switzerland) of 10 privately owned dogs suffering
from atopic dermatitis. AD was diagnosed by applying the
clinical criteria of Willemse and Prélaud [7, 8] and after
exclusion of differential diagnoses by intensive flea control
and an unsuccessful elimination diet for 8 weeks using a
commercial hydrolyzed protein diet, followed by a provo-
cation test and intradermal skin test (IDT), as well as serum
allergen-specific IgE determination. All dogs showed high
allergen-specific IgE in serum and were tested positive for
house dust or forage mites in the IDT. Before taking
biopsies, skin was cleared of secondary infections by
appropriate antimicrobial treatment. For comparison, also
biopsies of lesional skin from dogs suffering from non-
allergic inflammatory skin diseases were taken (five cases
of pemphigus folliaceus, three cases of leishmaniasis, and
two cases of acral lick dermatitis). Of healthy controls, skin
biopsies were taken as well as from the groin area and the
dorsal flank. Skin samples were frozen with OCT (Medite,
Nunningen, Switzerland) in isopentane (Sigma) cooled in
liquid nitrogen and then stored at −80°C until processing.
Cryosections of 5 μm thickness were cut with a cryotome
(HM560 MV, Microm International GmbH, Walldorf,
Germany), mounted on Superfrost Plus slides (Medite),
dried, and stored at −20°C until staining and analysis. For
each dog, the skin sections were stained by immunohisto-
chemistry with monoclonal antibodies against CD1c,
CD11b, CD11c, MHCII, CD206, CD14, IgE, and
MAC387 using the following procedure. Slides were thawed,
fixed in acetone (Grogg Chemia AG, Stettlen, Switzerland)
with 0.5% H2O2 (Merck, Darmstadt, Germany) to block
endogenous peroxidase, and rinsed with PBS before
blocking with 5% normal goat serum (Dako) and
application of the primary antibody. For detection, the
kit K5003 (Dako) was used according to the manufacturer’s
instructions. Slides were then counterstained with hema-
toxylin, washed with PBS, and covered with Aquatex
(Merck). All slides were analyzed using a Zeiss Axiolab
microscope (Carl Zeiss AG, Feldbach, Switzerland) with
a crossline graticule (Carl Zeiss). Positive cells in the
epidermis were counted along an area of 3×300 μm of
the basement membrane and five fields of 100 μm2 of
the interfollicular areas in the upper dermis.
For double immunofluorescence detection of MHCII
combined with CD1c, CD11b, CD11c, CD14, CD206, IgE,
andMAC387, the mAbs were added simultaneously followed
by the secondary antibodies conjugated with anti-mouse Ig
Alexa fluor 594 (Invitrogen) and anti-rat IgFITC (Southern
Biotech), respectively. Nuclei were counterstained with
Hoechst 33258 (Sigma) before covering slides with fluores-
cent mounting medium (Dako). Slides were analyzed and
photographed with a Nikon Eclipse 80i microscope (Nikon
AG, Egg, Switzerland) using the Open lab 5 software
(Improvision, Perkin Elmer, Waltham, MA, USA) and a
Retiga 2000R camera (Qimaging, Surrey, Canada).
Using the NCSS 2004 software (NCSS, Kaysville, Utah,
USA), a one-way ANOVA Kruskal–Wallis multiple com-
parison Z value test was calculated for group comparison
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and a one-sample T test used for comparison of nonlesional
cAD skin to normal dorsal skin.
Results
Isolation and Phenotypic Characterization of Putative
Canine Skin DC
From the epidermis and dermis of normal control dogs, we
were able to isolate a distinct population of cells double positive
for MHCII together with CD1, CD11c, and CD80 (Fig 1a, b).
The frequency of these cells varied between 2% and 12% for
the epidermis and 2% and 9% for the dermis in healthy skin
of different animals (n=8). CD11b and CD86 expression was
more variable with low expression in the dermis and often
absence in the epidermis (data for CD11b not shown). In
normal skin, the putative DC did not express CD40, CD14,
and IgE (Fig 1a, b) and also lacked the lymphocyte markers
CD4, CD5, CD8, CD21, and CD45 (data not shown). Light
microscopic analyses confirmed the presence of cells with DC
morphology in these cell preparations (Fig. 1c).
In Situ Characterization of Canine Skin DC
To confirm the phenotypic characteristics of putative canine
skin DC, biopsies of normal dog skin were analyzed by
immunohistochemistry (Fig. 2). In the dermis and epidermis,
Fig. 1 Phenotype and morphol-
ogy of isolated canine skin DC.
The contour plots show double
staining of cells isolated from
skin explant cultures with
expression of MHCII together
with CD1c, CD11c, CD14,
CD40, CD80, CD86, CD206,
and IgE. Putative DC were
identified as MHCII expressing
cells which have migrated out of
the epidermis (a) and the dermis
(b). The regions show the posi-
tive populations, and the numb-
ers in the upper right corner
indicate the percentage of the
positive cells within the gate. In
c, a phase contrast photomicro-
graph of a putative isolated DC
(in the upper left corner) is
shown (×100 magnification).
The data are representative for
five different healthy animals
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all MHCII+ cells had a DC morphology and co-expressed
CD1c and CD11c. Using this technique, CD11b was
restricted to the dermis and only found on MHCII+ cells
with DC morphology. As with flow cytometry, some
MHCII+ cells in the dermis did not express CD11b.
Based on the morphology, the localization, and the pheno-
type resembling that of other mammals, we classified the major
population of canine skin DC as CD1+CD11c+MHCII+CD80+
cells. Because of this analogy to other species, DC present in
the epidermis were termed LC.
Frequency, Phenotype, and Localization of DC
in Inflammatory Canine Skin
With this information, our next aim was to characterize DC in
inflammatory skin. To this end, we compared ventral and
dorsal control skin with lesional skin of dogs suffering from
cAD or NAI (Fig. 3). Lesional skin showed a mild to severe
acanthosis and in the epidermis mild spongiosis with a
mononuclear infiltrate, as known in the published literature
[23]. In inflammatory skin diseases (cAD and NAI), we
observed an increase of CD1c+CD11c+MHCII+ DC in the
epidermis by at least a factor 2 compared with normal
skin (Figs. 4a and 5) and a 2-4-fold increase of
CD1c+CD11c+MHCII+ cells in the dermis (Figs. 4b and 5).
Under inflammatory conditions as well as in healthy skin,
CD11b expression was restricted to the dermis and not found
in the epidermis. Despite this general increase of DC, the
epidermis and dermis of cAD, but not the NAI skin, showed
an increase of IgE+ cells. In contrast, the increased number
of cells expressing CD206 or CD14 was restricted to the
dermis and found in both cAD and NAI skin. Within the
NAI group, this infiltrate was similar in the PF cases (n=5),
the leishmaniasis cases (n=3), and also the cases with lick
dermatitis (n=2). The appearance of cells expressing the
putative macrophage marker MAC387 was restricted to the
dermis and more prominent in NAI skin.
With respect to the expression of the above markers,
nonlesional dorsal skin biopsies of cAD dogs were
comparable with normal dorsal skin of control dogs, but
Fig. 2 Phenotype and localiza-
tion of canine skin DC in situ.
Photomicrographs of cryoslides
of normal dog skin double
stained for MHCII (green) in
combination with CD1c,
CD11b, and CD11c (all in red).
The left and right pictures are
from the identical skin area to
determine co-expression of the
marker. The data are representa-
tive for 10 different healthy
animals. The dotted line indi-
cates the localization of the
basal membrane. Scale bar
indicates 20 μm
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differed significantly to lesional skin with p values of
<0.001 (Fig. 4c, d).
As demonstrated in Fig. 4, in normal skin, LC were
located in the stratum basale, and dermal DC mostly just
below the dermo-epidermal junction; in lesional skin, LC
were scattered through the acanthotic epidermis (only in
NAI conditions) and in the upper dermis. Dendritic cells
in the epidermis and dermis co-expressed MHCII and
CD1c (Fig. 4a, the plots in the first two rows are from the
same areas). Based on this observation, as well as the fact
that all DC co-expressed MHCII (Figs. 1 and 2) and that
the frequency of MHCII+ cells was similar to that of CD1c
and CD11c in inflammatory conditions, we employed
double staining using MHCII together with CD206,
CD14, IgE, and MAC387 to investigate the relationship
of cells expressing these markers to the DC lineage
(Fig. 5b). The results showed that in all CD206+ cells,
only a subset of CD14+ and IgE+ cells, and no MAC387+
cells, co-expressed MHCII. This indicates that during
inflammatory conditions, another subset of putative DC
infiltrates with an MHCII+CD206+CD14+ phenotype as
well as putative macrophages characterized by MAC387
expression.
Discussion
The dog is genetically quite close to humans, shares the
same environment, and suffers similar spontaneously
occurring diseases. Therefore, it could be a particular
Fig. 3 DC frequency and distribution in healthy, atopic, and non-
allergic inflamed canine skin. Photomicrographs of cryoslides stained
with CD1c of skin biopsies of nonlesional (a) and lesional (b) atopic
skin, and NAI skin (c). Data are representative for 10 different animals
for each group. Scale bars indicate 25 μm
Fig. 4 Frequency of cells
expressing DC markers in
healthy, atopic, and non-allergic
inflamed canine skin. Cells
expressing the indicated markers
were counted in immunochemi-
cally labeled epidermis (a) and
dermis (b) obtained from
healthy dogs (light gray bars) as
well as from inflammatory skin
of animals diagnosed as cAD
(black bars) or NAI (dark gray
bars). The lower graphs show
normal dorsal skin of healthy
dogs (light gray) compared with
nonlesional cAD skin (black) for
the epidermis (c) and dermis (d).
The bars show the mean of 10
different animals with standard
deviations. 1) indicates statisti-
cally significant differences of
inflammatory skin to healthy
control dogs. 2) indicates statis-
tically significant differences
between cAD and NAI skin
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Fig. 5 Phenotype and localiza-
tion of canine DC in atopic and
non-allergic inflamed canine
skin. a Photomicrographs of
cryoslides of normal dog skin
(first column), lesional cAD skin
(middle column), and lesional
NAI (pemphigus foliaceus) skin
double stained for MHCII
(green) in combination with
CD1c (first two rows), and
single stained for CD11c,
CD206, CD14, and IgE (all in
red) are shown. The data are
representative for 10 different
animals in each group. In b,
cAD and NAI lesional skin were
double stained for MHCII
(green) together with CD206,
CD14, IgE, and MAC387 (all in
red) and the same field is
shown. The dotted line indicates
the localization of the basal
membrane. The data are repre-
sentative for three different
animals in each group. Scale bar
indicates 50 μm
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informative animal model for several human diseases such
as atopic dermatitis [1], asthma [24], hypothyroidism [25],
diabetes mellitus [26], autoimmune hemolytic anemia [27],
myopathy [28], and certain infectious diseases [29].
As recently reviewed by Marsella and Girolimo, cAD
shows many similarities with the corresponding human
disease, in terms of clinical signs, the distribution of the
lesions, the pathogenesis, and the immunology of inflam-
mation [1]. Based on the proposed critical role for DC in
the pathogenesis of this allergic skin disease in human
beings [2], and to provide further support for the canine
model for human AD, we performed a systematic charac-
terization of canine skin in healthy dogs compared with
animals with cAD or NAI skin diseases focusing on
potential DC marker expression.
Our data demonstrate that canine LC express CD1c,
CD11c, CD80, and MHCII, and differ from dermal DC by
lack of CD11b, although this marker is not expressed on all
dermal DC. It is important to note that this differentiation
was only evident using the immunohistochemical analyses.
The canine LC phenotype is comparable with the human
LC, which are CD1a+CD1c+MHCII+ [13], as well as with
porcine LC defined as CD1+MHCII+ cells in the epidermis
[30]. Similarities can also be found with human dermal DC
expressing CD1c, CD11c, CD80, CD86, andMHCII [13, 31].
As mentioned above, some canine dermal DC expressed
CD11b relating to reports of human dermal DC also partially
expressing this marker [32]. Our study also demonstrates that
the phenotype of the isolated DC resembles that of the in situ
stained cells with the exception of CD11b expression.
Fig. 5 (continued)
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One of the main changes in inflammatory skin was an
increase in the frequency of CD1c+CD11c+MHCII+ DC in
the dermis and epidermis. Typical for cAD was the
appearance of IgE+ LC and an increase in IgE+ dermal
DC comparable with several previous studies in dogs [21,
33–36] and in human AD, where an FcεRI+ DC infiltration
was observed [13, 15, 37, 38]. In fact, the high expression
ratio of FcεRI/FcεRII is a diagnostic marker for human AD
[39]. The importance of this could be a strong IgE-
dependent allergen capture and uptake followed by a potent
stimulation of T cells [38].
In NAI skin, the infiltrate was comparable with cAD
with the difference of missing IgE expression, the higher
numbers of infiltrating CD206+CD14+MHCII+ putative
DC, as well as the appearance of MAC387+ putative
macrophages. The latter were very scarce in normal and
cAD skin but rather frequent in other inflammatory skin
diseases, again comparable with human studies [14].
Based on our observation that canine monocyte-
derived DC remain CD14+ [40], we propose that the
CD206+CD14+MHCII+ cells represent IDEC, which are a
population of monocyte-derived DC that can populate
both the epidermis and the dermis under inflammatory
conditions [41]. The main difference between IDEC and
LC in humans is the lack of Birbeck granules in IDEC
[13]. LC in dogs do not have Birbeck granules [42], and
we found no reactivity of anti-Langerin antibodies known
to react with porcine LC [30]. Therefore, this discrimina-
tory marker is not available, and canine LC can only be
defined on the basis of location in healthy skin. Future
studies are required to determine the role of these putative
IDEC for Th1-mediated skin inflammation as has been
proposed for human AD [2]. Other DC subsets such as
plasmacytoid DC present in human skin [37] cannot yet be
characterized in the dog due to the lack of phenotypic
information.
The different phenotypes found in the skin are in part
comparable with DC differentiated in vitro [40]. Canine DC in
normal skin resemble Flt3-ligand driven bone marrow-derived
DC, which are CD1c+CD11c+CD11blowMHCII+CD4−CD8−
and mostly CD206−. The higher levels of CD11b and CD206
on dermal DC in inflammatory skin conditions resemble more
the GM-CSF ligand-driven bone-marrow-derived DC.
Taken together, the present study characterized canine
LC, dermal DC, and infiltrating inflammatory DC in
normal, cAD, and NAI skin adding important information
about the canine DC system in healthy and diseased skin.
These findings and the identification of discriminatory
markers are important for further validation of the dog as a
model for human diseases, especially atopic dermatitis and
other immunological disorders. Our study confirms that on
one side, the cutaneous inflammatory milieu may attract
DC precursors and drive their differentiation to different
types of inflammatory DC and, on the other hand, that these
DC are likely to contribute specifically to disease processes
due to their importance in cutaneous homeostasis and their
immunological functions [13].
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